Fig. 2From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in JapanMaximum percentage reduction in target lesions (by Response Evaluation Criteria in Solid Tumors) during treatment with sorafenib plus IFN-αBack to article page